ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
A more complete description of the material terms of the Amendment and 2020 Plan
can be found in "Proposal 3: Approval of Amendment to the 2020 Equity Incentive
Plan" in the Company's definitive proxy statement originally filed with the
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
The Company held its 2022 Annual Meeting on
Proposal 1: Election of Three Class III Directors
Name of Director For Against Abstain Broker Non-Votes
124,756,293 30,358,126 124,656 34,048,151
Each director nominee was duly elected to serve until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
For Against Abstain 188,204,474 574,329 508,423
The stockholders ratified the appointment of
Proposal 3: Approval of Amendment to the 2020 Equity Incentive Plan
For Against Abstain Broker Non-Votes 114,164,354 40,929,508 145,213 34,048,151
The stockholders approved the amendment to the Company's 2020 Plan to increase the number of shares of the Company's common stock reserved thereunder.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
10.1+*Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended 10.2+* Form of Global Stock Option Agreement under thePacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended 10.3+* Form of Global Restricted Stock Unit Agreement under thePacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended 104* Cover Page Interactive Data File (embedded within the Inline XBRL document).
+ Indicates management contract or compensatory plan.
* Filed herewith.
© Edgar Online, source